Zobrazeno 31 - 40
of 52 726
pro vyhledávání: ''
Autor:
Mark Reedy, Komaraiah Palle, Chiquito J. Crasto, Rodney P. Rocconi, Chinnadurai Mani, Ranganatha R. Somasagara, Mohammad Athar, Kaushlendra Tripathi, Sandeep C. Chaudhary
Publikováno v:
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 9, Pp 1002-1015 (2021)
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 9, Pp 1002-1015 (2021)
Ovarian cancer (OC) is one of the most lethal type of cancer in women due to a lack of effective targeted therapies and high rates of treatment resistance and disease recurrence. Recently Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown pro
Publikováno v:
Toxicology and Industrial Health. 37:547-554
Bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate (TBPH) has been used as a replacement in some commercial flame-retardant mixtures. It is widely used in industrial products, so the probability of human exposure to TBPH is high. Yet, little is known abou
Publikováno v:
Drug Delivery
article-version (VoR) Version of Record
Drug Delivery, Vol 28, Iss 1, Pp 1810-1821 (2021)
article-version (VoR) Version of Record
Drug Delivery, Vol 28, Iss 1, Pp 1810-1821 (2021)
Lung cancer is a major cause of cancer-related deaths worldwide. Stimulus-sensitive hydrogels, which can be formed by responding to stimuli in the cancer microenvironment, have been widely studied as controlled-release carriers for hydrophobic antica
Autor:
Tjerk S.J. Opstal, Aernoud T.L. Fiolet, Amber van Broekhoven, Arend Mosterd, John W. Eikelboom, Stefan M. Nidorf, Peter L. Thompson, Michiel Duyvendak, J.W. Martijn van Eck, Eugène A. van Beek, Frank den Hartog, Charley A. Budgeon, Willem A. Bax, Jan G.P. Tijssen, Saloua El Messaoudi, Jan H. Cornel, S.M. Nidorf, X.F. Xu, M.A. Ireland, D. Latchem, A. Whelan, R. Hendriks, P. Salkani, I.W. Tan, A.G. Thompson, A.M. Morton, B.E. Hockings, P.L. Thompson, B. King, J.H. Cornel, H. Bakker-Lohmeijer, A. Mosterd, P. Bunschoten, S.H.K. The, S. van der Kooi, T. Lenderink, R.G.J.L. Lardinois, P.A.M. Hoogslag, A. de Vos, A. Jerzewski, S. Jansen, P.R. Nierop, M. van der Knaap, H.P. Swart, R. Kingma, J. Schaap, L.B. Blom, A.F.M. Kuijper, E. Bayraktar-Verver, M.W.J. van Hessen, W.C.T.C. Engelen, J.W.M. van Eck, N. van der Ven-Elzebroek, J.M.C. van Hal, I.M.J. Drost, F.R. den Hartog, D. van Wijk, E. van Beek, C. van der Horst, G.L. Bartels, M. Hendriks, C. de Nooijer, C. Welten, E. Ronner, A. Dijkshoorn, F.J. Prins, R.N.A. Rutten, D.P.W. Beele, I. Hendriks, A. van der Sluis, E.A. Badings, I.C.D. Westendorp, A. Melein, Tj.J. Römer, P. Bruines, R. van de Wal, I. Leenders - van Lieshout, M.E.W. Hemels, K. Meinen-Werner, M.R. de Groot, G. Post, M.W.C. Mulder, S. Stuij, E. van Nes, P. Luyten, J. Plomp, S.V. Veldmeijer, M.J. Asselman, P.A. Scholtus
Publikováno v:
Journal of the American College of Cardiology, 78, 859-866
Journal of the American College of Cardiology, 78(9), 859-866. Elsevier USA
Journal of the American College of Cardiology, 78, 9, pp. 859-866
LoDoCo2 Trial Investigators 2021, ' Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome ', Journal of the American College of Cardiology, vol. 78, no. 9, pp. 859-866 . https://doi.org/10.1016/j.jacc.2021.06.037
Journal of the American College of Cardiology, 78(9), 859-866. Elsevier USA
Journal of the American College of Cardiology, 78, 9, pp. 859-866
LoDoCo2 Trial Investigators 2021, ' Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome ', Journal of the American College of Cardiology, vol. 78, no. 9, pp. 859-866 . https://doi.org/10.1016/j.jacc.2021.06.037
Background: Colchicine reduces risk of cardiovascular events in patients post–myocardial infarction and in patients with chronic coronary disease. It remains unclear whether this effect is related to the time of onset of treatment following an acut
Autor:
Hayley M. Schrock, Thomas E. Prisinzano, Kevin B. Freeman, Kenneth J. Sufka, Bruce E. Blough, C. Austin Zamarripa, Tanya Pareek
Publikováno v:
Psychopharmacology (Berl)
RATIONALE: Triazole 1.1 is a novel kappa-opioid receptor (KOR) agonist reported to produce antinociception without KOR-typical adverse effects. When combined with the mu-opioid receptor (MOR) agonist, oxycodone, triazole 1.1 blocks oxycodone-induced
Publikováno v:
Immunopharmacology and Immunotoxicology. 43:594-598
Angiogenesis and inflammation exhibit a mutually reinforcing relationship in many human diseases. Vascular endothelial growth factor (VEGF) is one of the most important proangiogenic mediators. Conbercept is a novel VEGF inhibitor.Type II collagen-in
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 379:147-155
Intestinal mucositis, resulting from 5-fluorouracil (5-FU)-based chemotherapy, subjects patients to great pain and hampers cancer treatment progress. Puerarin, the major active ingredient in Pueraria lobata, exerts anti-inflammatory and anti-oxidativ
Publikováno v:
Pharmacological Reports
Background Preclinical and clinical studies have indicated that impaired endogenous synthesis of glutathione during early postnatal development plays a significant role in the pathophysiology of schizophrenia. Moreover, some studies have suggested th
Autor:
Yunpeng Du, Krzysztof Palczewski, Alyssa Dreffs, David A Antonetti, Chieh Allen Lee, Jie Tang, Timothy S. Kern, Haitao Liu, Henri Leinonen
Publikováno v:
Mol Pharmacol
Molecular pharmacology, vol 100, iss 5
Molecular pharmacology, vol 100, iss 5
We compared monotherapies and combinations of therapies that regulate G-protein coupled receptors (GPCR) with respect to their abilities to inhibit early stages of diabetic retinopathy (DR) in streptozotocin-diabetic mice. Metoprolol (MTP; 0.04-1.0 m
Publikováno v:
Anti-Cancer Drugs. 33:e525-e533
Cancer is related to the cellular proliferative state. Increase in cell-cycle regulatory function augments cellular folate pool. This pathway is therapeutically targeted. A number of drugs influences this metabolism, that is, folic acid, folinic acid